For example, KRAS/TP53 co-mutated tumors are associated with an inflamed immune microenvironment and increased tumor PD-L1 expression, whereas KRAS/STK11 co-mutated tumors are characterized as being cold, with a lack of T cell inflammation and lower PD-L1 expression irrespective of TMB. The gene discussed is STK11; the disease is neoplasm.